RxDoctor Payments DataLook up a doctor →

Allyson Dupre, NP

Nurse Practitioner · Baton Rouge, LANPI 1407475031

Payments from drug & device makers

$7,266in general payments, 2019–2025

Across 303 payments — averaging $23.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$772
  • Johnson & Johnson$729
  • Novartis$706
  • Daiichi Sankyo Inc.$413
  • Pharmacyclics LLC, An Abbvie Company$304
  • Bristol Myers Squibb$275
  • plus $4K from 53 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)26$772
Johnson & Johnson25$729
Novartis42$706
Daiichi Sankyo Inc.20$413
Pharmacyclics LLC, An Abbvie Company6$304
Bristol Myers Squibb16$275
Merck10$247
Pfizer12$228
Gilead(2 entities)10$228
E.r. Squibb & Sons, L.L.C.6$227
Eisai Inc.9$227
Exelixis Inc.6$203
GSK5$195
AbbVie7$183
Sanofi10$162
Mirati Therapeutics, Inc.2$144
Lilly USA, LLC7$140
Incyte Corporation7$139
Beigene USA, Inc.7$126
Aimmune Therapeutics, Inc.1$125
Fresenius Kabi USA, LLC1$105
Genentech USA, Inc.5$102
Jazz Pharmaceuticals Inc.5$99
Bayer4$81
Ipsen Biopharmaceuticals, Inc3$77
Sanofi-aventis U.S. LLC1$70
Pharmaessentia USA Corporation3$67
Tersera Therapeutics LLC3$66
Takeda Pharmaceuticals U.S.A., Inc.4$66
Blueprint Medicines Corporation3$56
Beone Medicines USA, Inc.3$56
ADC Therapeutics America, Inc.1$55
Seagen Inc.3$49
Puma Biotechnology, Inc.2$38
Array Biopharma Inc2$36
Karyopharm Therapeutics Inc.2$36
Morphosys, US Inc.2$29
Astellas Pharma US Inc1$25
Sirtex Medical Inc1$25
Otsuka America Pharmaceutical, Inc.1$25
Legend Biotech USA Inc.1$23
Adaptive Biotechnologies Corporation1$23
UCB, Inc.1$22
Regeneron Healthcare Solutions, Inc.1$20
Dendreon Pharmaceuticals LLC1$19
Macrogenics, Inc.1$19
Tempus AI, Inc1$19
Pharmacosmos Therapeutics Inc.1$18
Syndax Pharmaceuticals, Inc.1$17
Servier Pharmaceuticals LLC1$16
Sobi, Inc1$16
EMD Serono, Inc.1$15
Alnylam Pharmaceuticals Inc.1$15
G1 Therapeutics, Inc.1$15
Recordati_rare_diseases_inc.1$15
Myriad Genetic Laboratories, Inc.1$15
Mylan Institutional Inc.1$15
Amneal Pharmaceuticals LLC1$14
Stemline Therapeutics Inc.1$13

How this compares

$7,266 in reported general payments places this provider in the 95th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$22,077
Medicare patients
87
Services billed
346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →